Verily's Chief Technology Officer, Brian Otis, shared on Verily's blog that the company and Alcon have decided to put the glucose-sensing contact lens project on hold....
The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health....
Boston Scientific posted an 8-K disclosing the approval of a new global restructuring plan meant to support the company's effort to improve operating performance and meet anticipated market demands....
The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health....
Mike Fox, a client of Halunen Law, was a successful executive for MiMedx, a biopharmaceutical company that manufactures and sells regenerative and therapeutic biologics. Fox contends that his fortunes turned, however, when he challenged MiMedx and refused to participate in what he believed to be an illegal revenue recognition scheme....
Alivecor, maker of ECG software and hardware for the iPhone and other mobile devices, received another impressive victory this week as an international study found that their smartphone app was nearly as accurate as a 12-lead ECG in determining if a patient is having an ST-segment elevation myocardial infarction (STEMI). ...
Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously-announced intention of Novartis to spin off its eye care division as an independent, publicly-traded company. ...
Stereotaxis (OTCQX: STXS), reported financial results for the third quarter, showing overall recurring growth of 4% versus the prior year quarter and a reduction in system revenue by over 50%. ...
The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health....
Abiomed (NASDAQ: ABMD) announces the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, which show unloading the left ventricle with Impella CP for 30 minutes prior to reperfusion in patients presenting with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock is safe and feasible, when compared to Impella patients reperfused immediately....